laboratori corp america hldg
relief guidanc affirm
baselin growth
labcorp earn help provid relief thesi number
industri issu close revenu ep came better
previous lower expect rel estim organ growth
stronger across diagnost drug develop segment notabl covanc
deliv strong momentum gross organ growth net book-to-bil
diagnost organ volum flat despit headwind
pace calendar weather addit issu highlight
hospit refer test upbeat manag note trend
decemb combin better expect util
commentari reassur us underli lab oper environ remain
stabl diagnost margin weaker quarter though
view dynam temporari high degre confid
manag abil improv margin trajectori go forward covanc margin
strong quarter y/i
beyond quarter labcorp guidanc consist expect
help affirm baselin growth revenu growth consist
forecast underli growth diagnost
covanc addit ep expect rang
line manag prior commentari modest growth due pace
launchpad cost action share repurchas favor comp import
note guidanc call signific ramp year roughli flat
sequenti ep manag expect gener around free cash
flow deploy toward repurchas believ
labcorp valuat attract context strateg posit
diagnost drug develop associ opportun consolid
share time reiter ow rate
lh quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
barclay laboratori corp america hldg
laboratori corp america hldg lh
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight labcorp good track record
execut led solid organ growth
augment value-enhanc acquisit
time expect labcorp scale advantag across
diagnost drug develop gain share
substanti free cash flow use
augment growth
labcorp integr strategi covanc yield
higher sustain growth profil compani
addit lab industri consolid lead
acceler revenu ep growth upsid
case reflect upsid ep
reimburs headwind congression
action oner clinic lab
hospit begin greater penetr esoter test
volum downsid case reflect
downsid ep
barclay laboratori corp america hldg
labcorp earn help provid relief thesi number industri
issu close revenu ep came better previous lower
expect rel estim organ growth stronger across
diagnost drug develop segment notabl covanc deliv strong
momentum gross organ growth net book-to-bil
diagnost organ volum flat despit headwind pace calendar
weather addit issu highlight guidanc reduct
importantli labcorp commentari around hospit refer test
upbeat manag note trend improv decemb combin
better expect util commentari reassur us underli lab
oper environ remain stabl diagnost margin weaker
quarter though view dynam temporari high degre
confid manag abil improv margin trajectori go forward
covanc margin strong quarter y/i
beyond quarter labcorp guidanc consist expect
help affirm baselin growth revenu growth consist
forecast underli growth diagnost covanc
addit ep expect rang line
manag prior commentari modest growth due pace launchpad
cost action share repurchas favor comp import note
guidanc call signific ramp year roughli flat sequenti ep
manag expect gener around free cash flow
deploy toward repurchas believ labcorp valuat attract
context strateg posit diagnost drug develop
associ opportun consolid share time reiter ow rate
lab current trade discount averag ntm price-to-earnings
average spx barclay laboratori corp america hldg
lab trade discount though continu potenti share gain nation payor network open
labcorp issu revenu ep guidanc bracket prior
expect midpoint modestli model revenu growth
expect rang emb headwind divestitur
headwind fx addit manag
embed acquisit
contribut though quantifi expect import note
emb acquisit contribut model labcorp diagnost
expect show total growth embed growth rate
headwind divestitur headwind fx headwind pama
clf medicaid addit keep mind
payor contract chang unitedhealthcar aetna horizon net headwind
manag impli would volum model
organ volum anticip flat slightli covanc revenu growth
expect rang headwind fx result organ growth
guidanc
ep guidanc bracket initi expect ep
rang repres growth y/i labcorp expect ep headwind
pama impact cyber secur invest compani
forecast tax rate free cash flow guidanc
initi million capital-expenditure anticip repres revenu
labcorp expect ep line weaker normal trend due
expect revenu growth ramp covanc ramp launchpad save fx
barclay laboratori corp america hldg
pleas see report
risk/reward new payor
paradigm upgrad ow
build model headwind open payor network
aetna part cover steve valiquett continu
see renew end exclus contract nation payer real strateg
posit nation lab labcorp quest remind labcorp quest
recent announc new contract aetna view game-
changer industri previous labcorp quest exclus relationship
aetna respect open januari
overal believ new contract help break barrier nation
lab consolid share test improv patient experi payor
believ net yield modest benefit quest modest headwind
labcorp simpl math larger aetna would suggest quest
net beneficiari vice versa labcorp said fact labcorp
earn price increas critic element deal calculu
also cement truli paradigm shift industri
see anoth catalyst juli implement prefer
laboratori network think could big deal share save
prefer lab volum shift high-cost set first lab
industri volum shift high-cost provid toward prefer network
plan develop pool save share
provid instead commodit lab lab result qualiti metric
differenti particip price tool incentiv effici deliveri care
encourag util prefer network consid put
place econom incent patient physician adher network
guidanc dx dx dx organ organ growth barclay laboratori corp america hldg
would also first histori lab industri would includ waiv out-of-
pocket cost patient co-pay deduct encourag adopt given
rapid growth high-deduct health plan past decad believ could
drive strong incent patient better direct shift volum given
differenti invest quest labcorp put consum tool
real-tim auto adjud vs region peer two nation lab obviou
beneficiari prefer network implement
commentari prefer lab network
prefer lab network featur current contract laboratori care provid met higher standard
access cost data qualiti servic standard help us work lab improv care provid
current reach free-stand lab alreadi particip unitedhealthcar network invit
appli join prefer lab network program summer well announc inform
program along lab includ prefer lab network believ addit tier
prefer statu favor quest labcorp given compani advantag valu proposit consum tool
real-tim price capabl look forward learn addit detail
clearli much bigger opportun labcorp quest test consolid
lab across payor repres industri look back
past decad obviou nobodi origin nation exclus
contract nation lab nation payor patient old contract
allow region lab better penetr physician offic could arbitrag
benefit fact nation lab out-of-network one nation
payor drove higher price nation payor overal higher out-of-pocket
cost patient old payor paradigm drove complex physician would
field question patient around unexpect lab cost back in-
network remov unnecessari barrier compet nation lab
number get larg quickli current valuat believ investor
free call option potenti consolid upsid size outsid hospit lab
opportun around billion nation lab repres share everi
market share assum meaning price discount labcorp fee schedul
yield million addit revenu labcorp growth
estim labcorp estim increment margin would impli earn
growth around pull-through believ best outcom investor
lab industri consolid organ payor drive share nation
lab hand without need cash outlay
barclay laboratori corp america hldg
outsid hospit opportun
increment ep increment share gain
organ volum quarter declin embed organ growth
weather impact calendar impact along estim
lost share payor network estim underli util increas
y/i would solid result given confluenc factor labcorp rais
issu guidanc reduct includ headwind
lower hospit referr labcorp post y/i declin rev-per-req ex-food
sale attribut pama partial off-set test mix also believ
includ roughli headwind fx believ test mix genom
esoter test like help off-set price headwind
note organ reimburs growth adjust fx beacon lb
labcorp adjust mix
share piepric discount labcorp fee scheduleincrement labcorp rev mm increment revenu growthinc barclay laboratori corp america hldg
covanc deliv organ growth total growth forecast
growth rate basi unclear impact time
pass-through revenu quarter labcorp note perform
central lab especi strong first half earli develop
clinic develop busi primarili drove growth second half
book strong segment quarter compani continu
optimist around covanc competit market
covanc post net book-to-bil base mark
minor improv net book-to-bil someth
believ well receiv ttm basi labcorp book-to-bil
manag continu enthusiast around integr offer elabor
success compani area clinic trial recruit joint analyt
companion diagnost develop commerci compani note
covanc integr offer key attract new custom
millionsestestestestestestestestfisc year end dec labcorp metricstot growth revenu growth due volum revenu growth due pricingacquisit organ growth dx metricsgross lab lab growth acquir total access organ net new weather calendar underli ppa beacon organ lab rev medicar pama overal y/i organ growth barclay laboratori corp america hldg
segment organ growth labcorp
deal make labcorp slower compani announc two
laboratori servic partnership appalachian region healthcar baptist
organ growth modest compani done effect job
win new busi hospit partnership acquisit continu
believ effort provid better healthcar integr patient cost share
greater regul fda ldt reimburs pressur pama driver
share consolid toward effici provid labcorp quest
us market continu fragment share repres
two independ market leader believ reimburs pressur drive lab
consolid smaller competitor lack scale drive effici busi
margin come increas pressur rel quiet
deal front activ year labcorp kick deal activ
acquisit mt sinai outreach oper follow sizabl paml acquisit
ad million refer lab test busi affili provid health
system cathol health initi quest activ year acquisit
organ growth labcorp dxcovanc drug independ affili barclay laboratori corp america hldg
announc total eight deal headlin million acquisition/partnership
peacehealth
million acquisit
medfusion/clearpoint texa final sonic gotten action two jv
nyu nyc western connecticut network deal activ easili
eclips million lab industri revenu aggreg us
industri revenu look chart clear pace
partnership acquisit pick
 clinic laboratori acquisit partnership
believ uptick laboratori deal activ partial attribut pama
uncertainti major driver thesi industri updat
reimburs laboratori test went effect januari clearli
mind industri particip hospit laboratori view non-cor part
health system ideal area hospit gener save strike deal
labcorp quest allow hospit focu core busi continu
provid patient access qualiti laboratori servic mani hospit system
alreadi financi pressur pama repres increment risk drive
manag team chang decision-mak
octob labcorp announc multi-year laboratori partnership
baptist health two organ build upon exist refer laboratori
arrang go five year expand
arrang includ technic servic labcorp provid enhanc
laboratori technolog data analyt help health system improv patient
care baptist health oper eight hospital-bas laboratori fall
scope agreement
march labcorp announc multi-year partnership appalachian
region healthcar labcorp provid technic servic appalachian region
healthcar hospital-bas lab refer test servic entir network
facil clinician labcorp also grant appalachian region healthcar access
yeardealslabtarget/partnerdatetyp bynum patholog laboratori lab gener outreach medic outreach lab immunotec us lab lab lab acquisitionlabcorpappalachian region servicesquestcalifornia laboratori associ outreach acquisitionquestcleveland clinic servicesquesthartford outreach acquisitionquestshiel medic laboratori jvquestcap cod healthcar outreach acquisitionquestm fusion associ medic laboratori laboratori outreach acquisit servicessonicwestern connecticut health network venturequestmontefior health serviceslabcorpmount acquisitionlabcorpclearpath lab lab acquisitionquesthca serviceslabcorphenri mayo newel acquisitionquestclin laboratori partner hartford health outreach acquisit barclay laboratori corp america hldg
enhanc inform technolog data analyt help improv deliveri
patient care appalachian region healthcar oper hospit kentucki
februari labcorp announc agreement acquir patholog
associ medic laboratori paml mark largest laboratori acquisit
notabl deal labcorp paml larg hospital-own laboratori
provid refer outreach test servic hospit partner asset
own jv provid servic provid cathol
initi chi two largest hospit system countri addit paml
labcorp also plan acquir lab interest number joint ventur
believ would ultim lead complet ownership busi announc
transact clearli valid labcorp commit expand partnership
anchor hospit system come close heel acquisit
mt sinai outreach busi acquisit expand labcorp presenc
pacif northwest mid-west south give compani access serv two
largest health system
januari labcorp announc acquir clinic outreach
lab asset mount sinai health system nyc believ highlight
compani focu busi develop health system also repres
nice tuck-in acquisit compani system give labcorp access serv
anchor health system nyc market offer clinic patholog test
includ cytolog relat mdx test addit labcorp oper
mount sinai patient servic center psc region ad exist local
network psc opportun could includ collabor clinic trial
strengthen resourc covanc well work companion diagnost
medic educ term size estim transact could add
top line growth run-rat basi addit april
announc labcorp mount sinai enter contract
labcorp would work standard process test menu equip logist
health network seven acut care hospit
labcorp expect pama headwind lab revenu higher
expect labcorp note aggreg reimburs headwind
consist compani expect said compani
expect reimburs pressur impact medicar revenu medicaid ff
manag medicaid collect repres around total revenu
remind implement major chang medicar reimburs pama
januari forecast cut across compani medicar
medicaid revenu financi impact meaning yet manag given
medicar clf repres labcorp diagnost revenu total
medicaid could drive total exposur total revenu medicar
reimburs chang actual sizabl survey work interact
lab director suggest industri experi period meaning consolid
ultim believ smaller lab outsiz medicar exposur consolid
time either organ inorgan benefit labcorp quest industri
quot headlin medicar cut clf time roughli
code see rate decreas vs rate increas code
rate reduct greater labcorp quest estim around
top code see rate reduct annual first year reduct
increasingli sever routin test estim top
pleas see report
barclay laboratori corp america hldg
hcpc code clf spend cut altogeth top code
contribut clf spend almost million claim
design top code gener billion clf payment
top code cut genom health oncotyp dx top code
increas top code cut impli
medicar reimburs payment still weight median
averag addit anoth three test cut display magnitud
futur cut top code includ lipid panel reduct
code contribut nearli clf spend code drug
test def class new volum weight median pama reduct
overal continu believ signific rate reduct routin code
lead increas outsourc effici provid labcorp quest
top hcpc code clf spend
pleas see report
issu thought
pleas see report
takeaway clfs/pama
propos
potenti off-set horizon data collect
process similar process two import chang relat
definit applic lab influenc survey pool first chang
medicar advantag revenu exclud total medicar revenu threshold
second signific chang enabl hospit lab without uniqu npi
applic lab medicar revenu meet major
medicar revenu low expenditur threshold decis broaden definit
includ hospit lab come receiv much critic limit
hospit lab particip previou pama survey even addit hospit lab
particip still expect labcorp quest repres vast major data
submit part survey routin test though broader particip could
limit risk around addit cut clear chang view
expect medicar rate cut pama rate lock
hcpc codehcpc code descriptiontot claim linestot payment total nlaweight median payment w/ payment w/ payment w/ thyroid stim metabol cbc w/auto diff hemoglobin test def panel total test def parathormon psa free culture/coloni test def test def natriuret colorect breast cbc folic acid suscept barclay laboratori corp america hldg
data report period remind data report take place everi
year said think market may view posit given potenti
rate increas relief futur cut current model addit cut
labcorp report revenu billion forecast driven
organ growth acquir growth divest growth food
solut sale fx
labcorp dx revenu billion includ estim organ
growth coupl net divest headwind fx headwind drive
overal declin y/i came forecast total
declin lower meaning follow compani
guidanc reduct volum growth came estim
organ volum also forecast y/i
remind labcorp lower revenu forecast due
combin headwind lower hospit referr chang
network payor advers weather press releas labcorp call
weather impact calendar impact adjust covanc food
sale fx estim revenu per requisit decreas y/i line
forecast keep mind pama headwind within rev-per-req mix
drive chang
covanc revenu billion estim
revenu increas y/i organ growth adjust fx
 ttm book-to-bil
quarterli book-to-bil basi compar
basi
quarterli revenu million organ growth
adjust ebit ex-amort declin y/i million adj ebit
margin percentag net revenu declin y/i
estim adjust oper margin increas covanc
declin labcorp diagnost segment labcorp diagnost margin declin
y/i covanc drug develop margin improv
diagnost margin neg impact pama calendar impact
disposit busi weather adjust factor oper
margin would still declin also attribut
growth y/i barclay laboratori corp america hldg
overcapac personnel cost covanc saw benefit organ
demand covanc launchpad program acquisit labcorp
remain track gener million save expans launchpad
includ covanc well million cost synergi integr chiltern
end earn labcorp confirm diagnost launchpad
initi expect save million three year distribut save
expect equal part throughout
adj ebit margin segment ex-corpor overhead
sg repres net revenu quarter estim
import note due account chang
expens optic decreas percentag revenu
sg trend revenu
revenu higher expect ebitda margin
came expect due stronger revenu better sg
off-set higher expect cost revenu
sg abad debt lab barclay laboratori corp america hldg
margin trend revenu
flow oper came million estim
million cffo repres adjust net incom quarter adjust
million tax payment relat food test sale model
cffo would come estim quarter capital-expenditure million
repres net revenu y/i capit deploy consist
million share repurchas million debt repay million
acquisit labcorp repurchas million share deploy
million toward result labcorp announc updat share
repurchas author enabl billion buyback
labcorp continu gener signific free cash flow believ compani
flexibl activ capit deploy market compani
expect gener free cash flow rang million billion
million though note neg impact eurofin tax
payment million labcorp exit net debt ebitda
marginsebit margin barclay laboratori corp america hldg
use oper million
flowcapexlabcorp mm except ep reportedincom growth ebitda ebit pre-tax tax net adj net researchprior yearprior quarter barclay laboratori corp america hldg
million except per share dataestestestestestestestestfisc year end dec growth debt gross lab growth growth ex-fx organ growth increas gross cro net growth net margin net comp net net net intang loss equiti ebitda margin net net ebit margin net expens net debt pre-tax pre-tax incom tax net net average share average share ep ep increas item net incom adj net margin net adj net margin gross increas dilut increas ebit adj ebit margin barclay laboratori corp america hldg
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
